Vancomycin MIC at the Breakpoint
A 70-year-old woman with a prosthetic knee and diabetes has a deep wound infection after revision surgery. Intraoperative cultures grow methicillin-resistant Staphylococcus aureus (MRSA). The laboratory performs broth microdilution and reports a vancomycin MIC of 2 mg/L, which is at the susceptible breakpoint for S. aureus. The patient has been on vancomycin for 5 days with a therapeutic trough (15–20 mg/L), but the wound is not improving and she remains febrile. The surgeon asks whether to switch to daptomycin or add rifampin. The laboratory also notes the isolate is susceptible to daptomycin (MIC 0.5 mg/L), linezolid (MIC 2 mg/L), and trimethoprim-sulfamethoxazole.
1. Interpret the vancomycin MIC of 2 mg/L and explain its clinical significance.
Read the worked answer
A vancomycin MIC of 2 mg/L is technically susceptible for S. aureus but sits at the upper edge of the susceptible range, and outcomes for invasive MRSA infections with MICs at 2 mg/L are worse than for lower MICs-the so-called "MIC creep" concern. The laboratory should confirm the method, because broth microdilution is the reference method and results near the breakpoint can vary by method (e.g., Etest versus microdilution). The value should be reported with the method and interpreted as "susceptible, at breakpoint." Clinically, a failing patient with an MIC at 2 mg/L warrants consideration of an alternative agent rather than simply increasing the vancomycin dose, since higher doses increase nephrotoxicity without reliably improving killing.
2. Recommend a therapeutic approach and justify it.
Read the worked answer
Given clinical failure on vancomycin with a breakpoint MIC, switching to daptomycin (susceptible at 0.5 mg/L) is reasonable, at an appropriate weight-based dose, with monitoring of creatine kinase. Linezolid is an alternative, particularly if the source is a pulmonary infection-not the case here-or if daptomycin is contraindicated. Rifampin should not be added reflexively: it is used as combination therapy for prosthetic material infections because of biofilm activity, but only after the primary agent is optimized and only if the isolate is susceptible, and it has significant drug interactions and hepatotoxicity. The team should also address source control-prosthetic knee infection often requires debridement or exchange-because antibiotics alone rarely cure biofilm-associated prosthetic infections. Infectious disease consultation is warranted.
3. What should the laboratory do to ensure the result is reliable and communicated well?
Read the worked answer
The laboratory should confirm the MIC by a reference method (broth microdilution), verify purity and identification, and report the method and interpretation explicitly. It should avoid reporting only "S" without the numeric MIC, since the clinician needs the value to judge proximity to the breakpoint. If the isolate is sent to a reference laboratory, the laboratory should communicate the pending result and not delay the clinical decision. The report should note that MICs at the breakpoint have been associated with poorer outcomes, and the laboratory should offer to test additional agents (daptomycin, linezolid) if not already done. Clear communication of method and value supports the stewardship decision.